This article is more than 5 years old. Information may no longer be current.
Real-world anti-VEGF injections produce slight decrease in IOP
BOSTON — A “significant but small decrease” in IOP was seen in patients receiving anti-VEGF injections, according to real-world analysis of IRIS Registry data presented in a poster here at the American Society of Retina Specialists meeting.
However, while instances of clinically relevant IOP increase in these patients were “relatively rare,” repeated injections of Avastin (bevacizumab, Genentech) were seen to increase risk more than injections of Lucentis (ranibizumab, Genentech) or Eylea (aflibercept, Regeneron).
Elizabeth Atchison, MD, and colleagues presented the findings of a post hoc analysis of patients in the AAO IRIS (Intelligent Research in Sight) Registry receiving intravitreous anti-VEGF injections. The analysis included patients who received bevacizumab, ranibizumab or aflibercept in their right eye in 2013 or 2014 with at least 1 year of follow-up.
Results showed 1% to 3% of patients experienced a clinically significant sustained IOP elevation, defined as an IOP rise of 6 mm Hg or more resulting in IOP of 21 mm Hg or more. Patients receiving 12 or more injections of bevacizumab had a 4.1% risk of a sustained IOP elevation. The risk increased with additional injections, with patients receiving 25 or more injections having a 9.5% risk. – by Robert Linnehan
Reference:
Atchison E, et al. The real world effect of intravitreous anti-VEGF drugs on IOP. Presented at: American Society of Retina Specialists 35th Annual Meeting, Aug. 11-15, 2017; Boston.
Disclosure: Atchison reports no relevant financial disclosures.